Posted 3 weeks, 4 days ago (0 comments)
Horizon Therapeutics has announced a short-term supply disruption for TEPEZZA (TM), a medication approved earlier this year for the treatment of thyroid eye disease: "Beginning today, Horizon is delaying new patients starting on TEPEZZA. The Company will be communicating with TEPEZZA patients currently on therapy and the physicians who treat them. The Company’s priority will be to resume therapy for those patients as quickly as possible. If patients have additional questions, please contact Horizon Patient Services at 1-833-469-8331."
Please note that this information is being provided as a service to our patient and physician community, and that specific questions should be directed to Horizon Patient Services at the number above.